​​The Product

The BeamLine biopsy triaging system comprises BeamLine software, which carries the unique patent-pending diagnostic algorithm and user interface, combined with a commercially-available infrared spectrometer. The system has a relatively small footprint (approx. the size of a large laptop), can be installed near-patient and operated with minimal training. Samples do not need to be processed or damaged in any way and results for each specimen are returned within a few seconds. The system therefore integrates with existing clinical workflows with minimal disruption.

The diagnostic algorithm works on the principle of resect and discard. Samples are classed as 'Healthy'/'Benign' or 'Inconclusive'; any samples returning 'Inconclusive' results can be sent on to pathology along the normal pathway whilst 'Healthy'/'Benign' samples can be eliminated from further analyses.

The system uses infrared spectroscopy and can identify healthy and benign samples with 99% certainty.


The Science

Biopsies are scanned using attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, which measures the absorbance of mid-infrared light by the sample. The absorbance of infrared light of different frequencies gives information about the biochemical composition. Most molecules have distinct absorption band patterns allowing quantitative identification of multiple components in complex mixtures.

The absorbance bands of proteins, lipids, DNA, RNA, carbohydrates and a range of biochemical metabolites dominate human biopsy spectra.

Using these spectral patterns it is possible to detect subtle changes occurring during disease development, and hence, distinguish healthy samples from diseased. The BeamLine algorithm recognises spectral patterns unique to healthy and benign samples and is able to accurately separate these from all other spectral patterns. The biochemical changes associated with the different spectral patterns are believed to be due to differences in DNA, RNA and glycoprotein content in disease.